Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage: Economic evaluation of a phase III clinical trial in Europe and Australia

Henry Glick, Richard Willke, Daniel Polsky, Ted Liana, Wayne M. Alves, Neal Kassell, Kevin Schulman

Research output: Contribution to journalReview article


This study used data from a multinational phase III randomized, double- blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox®) in the treatment of aneurysmal subarachnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectiveness of this intervention.

Original languageEnglish (US)
Pages (from-to)145-160
Number of pages16
JournalInternational journal of technology assessment in health care
Issue number1
StatePublished - Jan 1 1998


ASJC Scopus subject areas

  • Health Policy

Cite this